Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
The Journal of Experimental Medicine|February 14, 2018
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancerKevin Shee, Wei Yang, John W Hinds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2016
Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast CancerWei Yang, Sarah R Hosford, Lloye M Dillon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cellsTodd W Miller, James T Forbes, Chirayu Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2009
Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancerChirayu Shah, Todd W Miller, Shelby K Wyatt, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
Pharmacological Induction of mesenchymal-epithelial transition chemosensitizes breast cancer cells and prevents metastatic progressionMeisam Bagheri, Gadisti Aisha Mohamed, Mohammed Ashick Mohamed Saleem, et al.
Cell Reports. Medicine|April 9, 2024
Pharmacological induction of chromatin remodeling drives chemosensitization in triple-negative breast cancerMeisam Bagheri, Gadisti Aisha Mohamed, Mohammed Ashick Mohamed Saleem, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancerNicole A Traphagen, Gary N Schwartz, Steven Tau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2020
AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer CellsRiley A Hampsch, Jason D Wells, Nicole A Traphagen, et al.
Breast Cancer Research and Treatment|December 11, 2014
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancerJennifer R Bean, Sarah R Hosford, Lynn K Symonds, et al.
Biorxiv : the Preprint Server for Biology|October 10, 2024
Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylationSteven Tau, Mary D Chamberlin, Huijuan Yang, et al.
Pageof 12